Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm
share announcement

Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 13395

Special Issue Editors

Prof. Mikihiro Fujiya

E-Mail
Guest Editor
Gastroenterology and Endoscopy, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University. 2-1-1-1, Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan
Interests: oncology; cell biology; clinical study; endoscopy
Prof. Dr. Kentaro Moriichi

E-Mail
Guest Editor
Gastroenterology and Endoscopy, Division of Metabolism and Biosystemic Science, Gastroenterology, and Hematology/Oncology, Department of Medicine, Asahikawa Medical University. 2-1-1-1, Midorigaoka-higashi, Asahikawa, Hokkaido 078-8510, Japan
Interests: oncology; molecular biology; clinical study; endoscopy

Special Issue Information

Dear Colleagues,

Colorectal cancer (CRC) is one of the major causes of death worldwide. The pathogenesis of colorectal neoplasms, including initiation as well as progression, remains unclear; however, sequential genetic and epigenetic alterations are known to be associated with the pathogenesis of CRC.

The diagnostic methods, including screening procedures and intervals, and therapeutic strategy, particularly chemotherapy with low molecular weight compounds and molecular-targeting therapies, are constantly changing.

The objective of this special issue is to gather original articles and reviews concerning new knowledge on adenocarcinoma, adenoma, adenomatous polyposis coli, and other types of colorectal neoplasms. This special issue will focus on the current status and challenges in research, as well as clinical procedures for the treatment of colorectal neoplasms, covering topics that include basic studies, technical developments, and the clinical management of CRC patients.

Prof. Mikihiro Fujiya
Prof. Dr. Kentaro Moriichi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Colorectal neoplasms
  • Pathogenesis
  • Chemotherapies
  • Molecular-targeting
  • Therapies
  • Screening
  • Clinical management
  • Colitis-associated neoplasms

Published Papers (6 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Editorial

Jump to: Research, Review

3 pages, 185 KiB  
Editorial
Cancer Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, and Colitis-Associated Neoplasia: A Special Issue
by Kentaro Moriichi and Mikihiro Fujiya
Cancers 2023, 15(4), 1328; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15041328 - 20 Feb 2023
Viewed by 1119
Abstract
Recent technological advancements have enabled us to analyze a variety of aspects of colorectal cancer (CRC), including both clinical and basic science [...] Full article
(This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm)

Research

Jump to: Editorial, Review

12 pages, 651 KiB  
Article
Preoperative Diagnostic Uncertainty in T2–T3 Rectal Adenomas and T1–T2 Adenocarcinomas and a Therapeutic Dilemma: Transanal Endoscopic Surgery, or Total Mesorectal Excision?
by Xavier Serra-Aracil, Noemi Montes, Laura Mora-Lopez, Anna Serracant, Carles Pericay, Pere Rebasa and Salvador Navarro-Soto
Cancers 2021, 13(15), 3685; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13153685 - 22 Jul 2021
Cited by 1 | Viewed by 1583
Abstract
Background: Endorectal ultrasound and rectal magnetic resonance are sometimes unable to differentiate between stages T2 and T3 in rectal adenomas that are possible adenocarcinomas, or between stages T1 and T2 in rectal adenocarcinomas. These cases of diagnostic uncertainty raise a therapeutic dilemma: transanal [...] Read more.
Background: Endorectal ultrasound and rectal magnetic resonance are sometimes unable to differentiate between stages T2 and T3 in rectal adenomas that are possible adenocarcinomas, or between stages T1 and T2 in rectal adenocarcinomas. These cases of diagnostic uncertainty raise a therapeutic dilemma: transanal endoscopic surgery (TES) or total mesorectal excision (TME)? Methods: An observational study of a cohort of 803 patients who underwent TES from 2004 to 2021. Patients operated on for adenoma (group I) and low-grade T1 adenocarcinoma (group II) were included. The variables related to uncertain diagnosis, and to the definitive pathological diagnosis of adenocarcinoma stage higher than T1, were analyzed. Results: A total of 638 patients were included. Group I comprised 529 patients, 113 (21.4%) with uncertain diagnosis. Seventeen (15%) eventually had a pathological diagnosis of adenocarcinoma higher than T1. However, the variable diagnostic uncertainty was a risk factor for adenocarcinoma above T1 (OR 2.3, 95% CI 1.1–4.7). Group II included 109 patients, eight with uncertain diagnosis (7.3%). Two patients presented a definitive pathological diagnosis of adenocarcinoma above T1. Conclusions: On the strength of these data, we recommend TES as the initial indication in cases of diagnostic uncertainty. Multicenter studies with larger samples for both groups should now be performed to further assess this strategy of initiating treatment with TES. Full article
(This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm)
►▼ Show Figures

Figure 1

15 pages, 5116 KiB  
Article
Transcriptome Profiling and Metagenomic Analysis Help to Elucidate Interactions in an Inflammation-Associated Cancer Mouse Model
by Kazuko Sakai, Marco A. De Velasco, Yurie Kura and Kazuto Nishio
Cancers 2021, 13(15), 3683; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13153683 - 22 Jul 2021
Cited by 7 | Viewed by 3149
Abstract
Colitis is a risk factor for colorectal cancer (CRC) and can change the dynamics of gut microbiota, leading to dysbiosis and contributing to carcinogenesis. The functional interactions between colitis-associated CRC and microbiota remain unknown. In this study, colitis and CRC were induced in [...] Read more.
Colitis is a risk factor for colorectal cancer (CRC) and can change the dynamics of gut microbiota, leading to dysbiosis and contributing to carcinogenesis. The functional interactions between colitis-associated CRC and microbiota remain unknown. In this study, colitis and CRC were induced in BALB/c mice by the administration of dextran sodium sulfate (DSS) and/or azoxymethane (AOM). Whole transcriptome profiling of normal colon was then performed, and gene set enrichment analysis (GSEA) revealed enriched fatty acid metabolism, oxidative phosphorylation, and PI3K-Akt-mTOR signaling in the tissues from DSS/AOM mice. Additionally, immunohistochemical staining showed increased expression levels of phosphorylated S6 ribosomal protein, a downstream target of the PI3K-Akt-mTOR pathway in the inflamed mucosa of DSS/AOM mice. Fecal microbes were characterized using 16S rDNA gene sequencing. Redundancy analysis demonstrated a significant dissimilarity between the DSS/AOM group and the others. Functional analysis inferred from microbial composition showed enrichments of the sphingolipid signal and lipoarabinomannan biosynthetic pathways. This study provides additional insights into alterations associated with DSS/AOM-induced colitis and associates PI3K-Akt-mTOR, sphingolipid-signaling and lipoarabinomannan biosynthetic pathways in mouse DSS/AOM-induced colitis. Full article
(This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm)
►▼ Show Figures

Figure 1

13 pages, 862 KiB  
Article
Consistent Major Differences in Sex- and Age-Specific Diagnostic Performance among Nine Faecal Immunochemical Tests Used for Colorectal Cancer Screening
by Anton Gies, Tobias Niedermaier, Elizabeth Alwers, Thomas Hielscher, Korbinian Weigl, Thomas Heisser, Petra Schrotz-King, Michael Hoffmeister and Hermann Brenner
Cancers 2021, 13(14), 3574; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13143574 - 16 Jul 2021
Cited by 8 | Viewed by 1864
Abstract
Evidence on diagnostic performance of faecal immunochemical tests (FITs) by sex and age is scarce. We aimed to evaluate FIT performance for detection of advanced colorectal neoplasia (AN) by sex and age across nine different FIT brands in a colonoscopy-controlled setting. The faecal [...] Read more.
Evidence on diagnostic performance of faecal immunochemical tests (FITs) by sex and age is scarce. We aimed to evaluate FIT performance for detection of advanced colorectal neoplasia (AN) by sex and age across nine different FIT brands in a colonoscopy-controlled setting. The faecal samples were obtained from 2042 participants of colonoscopy screening. All eligible cases with AN (n = 216) and 300 randomly selected participants without AN were included. Diagnostic performance for detection of AN was assessed by sex and age (50–64 vs. 65–79 years for each of the nine FITs individually and for all FITs combined. Sensitivity was consistently lower, and specificity was consistently higher for females as compared with males (pooled values at original FIT cutoffs, 25.7% vs. 34.6%, p = 0.12 and 96.2% vs. 90.8%, p < 0.01, respectively). Positive predictive values (PPVs) were similar between both sexes, but negative predictive values (NPVs) were consistently higher for females (pooled values, 91.8% vs. 86.6%, p < 0.01). Sex-specific cutoffs attenuated differences in sensitivities but increased differences in predictive values. According to age, sensitivities and specificities were similar, whereas PPVs were consistently lower and NPVs were consistently higher for the younger participants. A negative FIT is less reliable in ruling out AN among men than among women and among older than among younger participants. Comparisons of measures of diagnostic performance among studies with different sex or age distributions should be interpreted with caution. Full article
(This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm)
►▼ Show Figures

Figure 1

21 pages, 2829 KiB  
Article
The Identification of RNA-Binding Proteins Functionally Associated with Tumor Progression in Gastrointestinal Cancer
by Hiroaki Konishi, Shin Kashima, Takuma Goto, Katsuyoshi Ando, Aki Sakatani, Hiroki Tanaka, Nobuhiro Ueno, Kentaro Moriichi, Toshikatsu Okumura and Mikihiro Fujiya
Cancers 2021, 13(13), 3165; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13133165 - 24 Jun 2021
Cited by 5 | Viewed by 2056
Abstract
Previous investigations have indicated that RNA-binding proteins (RBPs) are key molecules for the development of organs, differentiation, cell growth and apoptosis in cancer cells as well as normal cells. A bioinformatics analysis based on the mRNA expression and a somatic mutational database revealed [...] Read more.
Previous investigations have indicated that RNA-binding proteins (RBPs) are key molecules for the development of organs, differentiation, cell growth and apoptosis in cancer cells as well as normal cells. A bioinformatics analysis based on the mRNA expression and a somatic mutational database revealed the association between aberrant expression/mutations of RBPs and cancer progression. However, this method failed to detect functional alterations in RBPs without changes in the expression, thus leading to false negatives. To identify major tumor-associated RBPs, we constructed an siRNA library based on the database of RBPs and assessed the influence on the growth of colorectal, pancreatic and esophageal cancer cells. A comprehensive analysis of siRNA functional screening findings using 1198 siRNAs targeting 416 RBPs identified 41 RBPs in which 50% inhibition of cell growth was observed in cancer cells. Among these RBPs, 12 showed no change in the mRNA expression and no growth suppression in non-cancerous cells when downregulated by specific siRNAs. We herein report for the first time cancer-promotive RBPs identified by a novel functional assessment using an siRNA library of RBPs combined with expressional and mutational analyses. Full article
(This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm)
►▼ Show Figures

Figure 1

Review

Jump to: Editorial, Research

16 pages, 1311 KiB  
Review
T Cell Aging in Patients with Colorectal Cancer—What Do We Know So Far?
by Oana-Maria Thoma, Markus F. Neurath and Maximilian J. Waldner
Cancers 2021, 13(24), 6227; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers13246227 - 11 Dec 2021
Cited by 6 | Viewed by 2775
Abstract
Colorectal cancer (CRC) continues to be one of the most frequently diagnosed types of cancers in the world. CRC is considered to affect mostly elderly patients, and the number of diagnosed cases increases with age. Even though general screening improves outcomes, the overall [...] Read more.
Colorectal cancer (CRC) continues to be one of the most frequently diagnosed types of cancers in the world. CRC is considered to affect mostly elderly patients, and the number of diagnosed cases increases with age. Even though general screening improves outcomes, the overall survival and recurrence-free CRC rates in aged individuals are highly dependent on their history of comorbidities. Furthermore, aging is also known to alter the immune system, and especially the adaptive immune T cells. Many studies have emphasized the importance of T cell responses to CRC. Therefore, understanding how age-related changes affect the outcome in CRC patients is crucial. This review focuses on what is so far known about age-related T cell dysfunction in elderly patients with colorectal cancer and how aged T cells can mediate its development. Last, this study describes the advances in basic animal models that have potential to be used to elucidate the role of aged T cells in CRC. Full article
(This article belongs to the Special Issue Cancers Research in Adenocarcinoma, Adenoma, Adenomatous Polyposis Coli, Colitis-Associated Neoplasm)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-6
Back to TopTop